NCT06343298招募中2 期
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS MANP WHEN ADMINISTERED ONCE DAILY FOR 42 DAYS IN PARTICIPANTS WITH DIFFICULT TO CONTROL HYPERTENSION/RESISTANT HYPERTENSION
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 29
- 主要终点
- Change from baseline in mean daytime SBP derived from 24-hour ABPM at approximately Day 42.
研究概览
简要总结
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:
- •Male or female subjects aged 18 - 80 years, inclusive, at the screening visit.
- •Female subjects must not be of childbearing potential
- •Subjects must be taking appropriate doses of 3 or more antihypertensive drugs with different mechanisms of action. One of which must be a diuretic and the other must be an ACEi or ARB at atleast 50% of the maximum recommended dose for hypertension.
- •Subjects must have a seated (5 minutes) systolic blood pressure ≥ 140 mmHg and SBP ≥135 mmHg by ABPM prior to randomization (T1).
- •Subjects must have a CKD-EPI eGFR ≥ 30 mL/min/1.73m2
- •A subset of the subjects with an eGFR between 20-30 ml/min/1.73m2 will be included, not to exceed 10% of the total study subjects.
- •Subjects must have a BMI between 18 - 40 kg/m
- •Subjects who engage in sexual intercourse in which their partner could become pregnant must agree to use a barrier method of birth control (i.e., vaginal/penile condom) with spermicide for the duration of the study and for 90 days after the last dose of study drug or be at least 6 weeks post-vasectomy with confirmation by post-vasectomy semen analysis. In addition, subjects may not donate sperm for the duration of the study and for 90 days after the last dose of study drug.
排除标准
- •Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:
- •Subjects with an average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg at Screening (SV), or prior to randomization at T
- •Subjects with a history of secondary hypertension, including but not limited to coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's disease, pheochromocytoma, and polycystic kidney disease. If the subject has not previously been evaluated for secondary hypertension, investigators are responsible for evaluating all potential secondary causes of hypertension in accordance with current practices and clinical guidelines before entering the patient into the study.
- •Subjects with an HbA1c ≥ 8% at screening (SV)
- •Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 months of the Screening Visit; or sick sinus syndrome or second- or third-degree atrioventricular block, or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia.
- •Subjects who have an implanted cardioverter defibrillator (ICD) that has been fired for any arrhythmia within 3 months of Screening (SV) or implanted pacemakers.
- •Subjects with congestive heart failure (New York Heart Association [NYHA] class II-IV)
- •Subjects with hemodynamically significant valvular heart disease
- •Subjects undergoing hemodialysis or peritoneal dialysis, or history of renal transplant.
- •Subjects who have diagnosis or recurrence of malignancy within the past 3 years
- •Subjects with a documented history of sleep apnea, with a prescription for CPAP therapy.
- •Women of childbearing potential
- •Subjects who are pregnant or breastfeeding
研究组 & 干预措施
Placebo-matched control
Placebo Comparator
Placebo-matched vehicle (vehicle minus the active component)
干预措施: Placebo Matched control (Other)
MANP
Active Comparator
MANP in vehicle
干预措施: MANP (Drug)
结局指标
主要结局
Change from baseline in mean daytime SBP derived from 24-hour ABPM at approximately Day 42.
时间窗: Approximately 42 days
ABPM
Incidence and severity of Adverse events through 4- weeks post end of treatment.
时间窗: Approximately 10 weeks
Safety
Incidence and severity of Serious Adverse Events through 4- weeks post end of treatment.
时间窗: Approximately 10 weeks
Safety
Incidence and severity of Treatment Emergent Adverse Events through 4- weeks post end of treatment.
时间窗: Approximately 10 weeks
Safety
次要结局
- Change in Clinic sitting systolic blood pressure(Approximately 42 days)
- Pharmacokinetics - Cmax(Approximately 42 days)
- Pharmacokinetics - Tmax(Approximately 42 Days)
- Anti-drug Antibody(Approximately 10 weeks)
研究者
研究点 (29)
Loading locations...
相似试验
已完成
2 期
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaFriedreich AtaxiaNCT05579691Larimar Therapeutics, Inc.28
已完成
2 期
Study of SPG601 in Adult Men With Fragile X SyndromeFragile X SyndromeNCT06413537Spinogenix10
已完成
2 期
Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesIgA NephropathyC3 GlomerulonephritisMembranous NephropathyDense Deposit DiseaseLupus NephritisNCT03453619Apellis Pharmaceuticals, Inc.21
已完成
3 期
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2NCT01733758GlaxoSmithKline494
已完成
2 期
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and OlderSARS-CoV-2NCT04405076ModernaTX, Inc.660